Organization Description
Founded as Rejuveron Life Sciences AG, Centenara Labs supports pioneers in the field of aging and rejuvenation research to transform their scientific discoveries into medicines that help people to live healthier, longer lives. “Under our business model, Centenara Labs invests in portfolio companies, which are co-founded with world-class scientific entrepreneurs, each of which focuses on one or more of the hallmarks of aging.”
Centenara was co-founded in 2019 by Dr. Matthias Steger (who also serves as CEO of Endogena Therapeutics) and investor Christian Angermayer. In August 2023, then-Rejuveron raised $75 million in dual tranche series B and convertible loan financing. It rebranded as Centenara one year later. As of August 2025, we judge it likely that both Endogena and Centenara have ceased operation.
Endogena Therapeutics
Endogena Therapeutics is a clinical-stage biotech company in Centenara’s portfolio. It discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs that have deteriorated due to aging and genetic diseases. Their platform uses phenotypic screening to discover small molecules that activate, differentiate, or otherwise therapeutically modulate the activity of native adult stem and progenitor cells to effect controlled repair of tissues injured by disease, injury, or degenerative aging processes.
Its most advanced candidate was is EA-2353, a small molecule that targets progenitor cells in the ciliary body to promote retinal regeneration in retinitis pigmentosa (RP). In June of 2022, Endogena-affiliated scientists reported interim results of a Phase I trial of EA-2353 in people with RP, which found prelimintary evidence of safety and efficacy at the first of an anticipated two years. However, the ClinicalTrials.gov entry for this trial states that it was terminated once all patients had completed at least one year of safety followup instead of the intended two “due to a corporate decision, not any safety concerns of EA-2353.”
RejuverSen SL
RejuverSen SL is or was a Swiss longevity biotech startup working to develop senolytic therapies against age-related disease cofounded by Dr. Manuel Serrano. With their lead program intended to clear senescent cells that are created after chemotherapy by inhibiting the PD-L2 ligand to enable senescent cell destruction by the immune system.
Their lead program, RST-001, targets senescent cells generated by and residual after triple-negative breast cancer, using a proprietary antibody that is currently in IND-enabling studies, and expected it to enter clinical research in 2025. Its other programs were RST-002 (for chronic kidney disease idiopathic pulmonary fibrosis (IPF) and RST-003 (listed for unspecified fibrotic disease(s), with an icon suggesting liver cirrhosis
Related News
